Dr. Ajay Kundra

Hematology Oncology | Hospital Medicine | Hematology
834 Sheridan St, 
Port Townsend, WA 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Offers Telehealth
834 Sheridan St, 
Port Townsend, WA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Ajay Kundra is a Hematologist Oncology specialist and a Hospital Medicine provider in Port Townsend, Washington. Dr. Kundra is rated as an Experienced provider by MediFind in the treatment of Laryngeal Cancer. His top areas of expertise are Lung Cancer, Pleuropulmonary Blastoma, Paget Disease of the Breast, Multiple Myeloma, and Bone Marrow Aspiration. Dr. Kundra is currently accepting new patients.

His clinical research consists of co-authoring 7 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Hospital Medicine
Hematology
Licenses
Internal Medicine in WA
Hospital Affiliations
St Joseph Hospital
Providence Regional Medical Center Everett
Harrison Medical Center
Jefferson Healthcare
Olympic Medical Center
Languages Spoken
English
Hindi
Punjabi
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

JEFFERSON COUNTY PUBLIC HOSPITAL DISTRICT NO 2
834 Sheridan St, Port Townsend, WA 98368

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

A Phase 2/3, Multicenter Randomized Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (RR DLBCL)
A Phase 2/3, Multicenter Randomized Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (RR DLBCL)
Enrollment Status: Recruiting
Publish Date: October 03, 2025
Intervention Type: Drug
Study Drugs: Selinexor, Rituximab, Gemcitabine, Dexamethasone, Cisplatin
Study Phase: Phase 2/Phase 3
A Randomized Phase 3 Double-Blinded Study Comparing the Efficacy and Safety of Niraparib to Placebo in Participants With Either HER2-Negative BRCA-Mutated or Triple-Negative Breast Cancer With Molecular Disease Based on Presence of Circulating Tumor DNA After Definitive Therapy (ZEST)
A Randomized Phase 3 Double-Blinded Study Comparing the Efficacy and Safety of Niraparib to Placebo in Participants With Either HER2-Negative BRCA-Mutated or Triple-Negative Breast Cancer With Molecular Disease Based on Presence of Circulating Tumor DNA After Definitive Therapy (ZEST)
Enrollment Status: Active_not_recruiting
Publish Date: July 16, 2025
Intervention Type: Drug
Study Drug: Niraparib
Study Phase: Phase 3
An Adaptive Phase III, Multicenter, Randomized, Open-Label, Controlled Study of M7824 (Bintrafusp Alfa) Versus Pembrolizumab as a First-line Treatment in Patients With PD-L1 Expressing Advanced Non-small Cell Lung Cancer
An Adaptive Phase III, Multicenter, Randomized, Open-Label, Controlled Study of M7824 (Bintrafusp Alfa) Versus Pembrolizumab as a First-line Treatment in Patients With PD-L1 Expressing Advanced Non-small Cell Lung Cancer
Enrollment Status: Completed
Publish Date: April 08, 2025
Intervention Type: Drug
Study Drugs: M7824, Pembrolizumab
Study Phase: Phase 3
A Global Multicenter Randomized Placebo-Controlled Phase 3 Trial To Compare The Efficacy And Safety Of Fruquintinib Plus Best Supportive Care To Placebo Plus Best Supportive Care In Patients With Refractory Metastatic Colorectal Cancer
A Global Multicenter Randomized Placebo-Controlled Phase 3 Trial To Compare The Efficacy And Safety Of Fruquintinib Plus Best Supportive Care To Placebo Plus Best Supportive Care In Patients With Refractory Metastatic Colorectal Cancer
Enrollment Status: Completed
Publish Date: April 04, 2025
Intervention Type: Drug
Study Drug: Fruquintinib
Study Phase: Phase 3
A Phase I/II Study of the SV-BR-1-GM Regimen in Metastatic or Locally Recurrent Breast Cancer Patients in Combination With Retifanlimab
A Phase I/II Study of the SV-BR-1-GM Regimen in Metastatic or Locally Recurrent Breast Cancer Patients in Combination With Retifanlimab
Enrollment Status: Enrolling_by_invitation
Publish Date: February 04, 2025
Intervention Type: Drug, Biological
Study Drugs: SV-BR-1-GM, INCMGA00012, Low Dose Cyclophosphamide, Interferon Inoculation, Epacadosta
Study Phase: Phase 1/Phase 2
MOUNTAINEER: A Phase II, Open Label Study of Tucatinib Combined With Trastuzumab in Patients With HER2+ Metastatic Colorectal Cancer
MOUNTAINEER: A Phase II, Open Label Study of Tucatinib Combined With Trastuzumab in Patients With HER2+ Metastatic Colorectal Cancer
Enrollment Status: Completed
Publish Date: November 26, 2024
Intervention Type: Drug
Study Phase: Phase 2
A Randomized, Double-Blind, Placebo-Controlled Trial of Tomivosertib in Combination With Anti-PD-(L)1 Therapy in Subjects With NSCLC as First Line Therapy or When Progressing on Single-Agent First-Line Anti PD (L)1 Therapy
A Randomized, Double-Blind, Placebo-Controlled Trial of Tomivosertib in Combination With Anti-PD-(L)1 Therapy in Subjects With NSCLC as First Line Therapy or When Progressing on Single-Agent First-Line Anti PD (L)1 Therapy
Enrollment Status: Active_not_recruiting
Publish Date: April 30, 2024
Intervention Type: Biological, Drug
Study Drugs: Tomivosertib, Pembrolizumab
Study Phase: Phase 2
A Multicenter, Open-Label, Randomized-Controlled Study of Abemaciclib, a CDK4 and 6 Inhibitor, in Combination With Fulvestrant Compared to Chemotherapy in Women With HR Positive, HER2 Negative Metastatic Breast Cancer With Visceral Metastases
A Multicenter, Open-Label, Randomized-Controlled Study of Abemaciclib, a CDK4 and 6 Inhibitor, in Combination With Fulvestrant Compared to Chemotherapy in Women With HR Positive, HER2 Negative Metastatic Breast Cancer With Visceral Metastases
Enrollment Status: Terminated
Publish Date: August 24, 2021
Intervention Type: Drug
Study Phase: Phase 4
View 7 Less Clinical Trials

7 Total Publications

Programmed Cell Death Receptor (PD-1) Ligand (PD-L1) expression in Philadelphia chromosome-negative myeloproliferative neoplasms.
Programmed Cell Death Receptor (PD-1) Ligand (PD-L1) expression in Philadelphia chromosome-negative myeloproliferative neoplasms.
Journal: Leukemia research
Published: August 08, 2018
Similar Doctors
Distinguished in Laryngeal Cancer
Dr. Cristina P. Rodriguez
Hematology Oncology | Hematology | Oncology
Distinguished in Laryngeal Cancer
Dr. Cristina P. Rodriguez
Hematology Oncology | Hematology | Oncology

The Association Of University Physicians

1701 Columbia Rd, 
Seattle, WA 
 (38.7 miles away)
206-598-3100
Languages Spoken:
English, Filipino, French, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Cristina Rodriguez is a Hematologist Oncology specialist and a Hematologist in Seattle, Washington. Dr. Rodriguez is rated as an Advanced provider by MediFind in the treatment of Laryngeal Cancer. Her top areas of expertise are Laryngeal Cancer, Anaplastic Thyroid Cancer, Thyroid Cancer, and Polymorphous Low Grade Adenocarcinoma. Dr. Rodriguez is currently accepting new patients.

Experienced in Laryngeal Cancer
Dr. Junfeng Wang
Hematology Oncology | Oncology | Hematology
Experienced in Laryngeal Cancer
Dr. Junfeng Wang
Hematology Oncology | Oncology | Hematology

Public Hospital Dist No 1 Skagit

307 S 13th St, Suite 100, 
Mount Vernon, WA 
 (30.5 miles away)
360-814-2146
Languages Spoken:
English, Mandarin, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Junfeng Wang is a Hematologist Oncology specialist and an Oncologist in Mount Vernon, Washington. Dr. Wang is rated as a Distinguished provider by MediFind in the treatment of Laryngeal Cancer. His top areas of expertise are Paget Disease of the Breast, Angiosarcoma, Inflammatory Breast Cancer, and Thrombocytopenia. Dr. Wang is currently accepting new patients.

Experienced in Laryngeal Cancer
Dr. Khaled A. Tolba
Hematology Oncology | Oncology
Experienced in Laryngeal Cancer
Dr. Khaled A. Tolba
Hematology Oncology | Oncology
825 Eastlake Ave E, 
Seattle, WA 
 (39.4 miles away)
206-520-5000
Languages Spoken:
English

Khaled Tolba is a Hematologist Oncology specialist and an Oncologist in Seattle, Washington. Dr. Tolba is rated as an Advanced provider by MediFind in the treatment of Laryngeal Cancer. His top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Lung Adenocarcinoma, and Pleuropulmonary Blastoma.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Kundra's expertise for a condition
ConditionClose
    View All 87 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile